GSK233705 + GW642444

GSK233705 + GW642444 is an investigational fixed-dose combination of two inhaled bronchodilators developed for the treatment of chronic obstructive pulmonary disease (COPD). GSK233705 is a long-acting muscarinic antagonist (LAMA), while GW642444 is a long-acting beta2-adrenoceptor agonist (LABA). The combination aims to provide enhanced bronchodilation by targeting two complementary pathways involved in airway smooth muscle relaxation, potentially improving lung function and symptom control in COPD patients. Both agents have been studied individually and together in clinical trials, including studies assessing safety, pharmacokinetics, and efficacy in healthy subjects and patients with COPD. The developer is GSK[1][2][4][5].